Ovarian Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Ovarian Cancer stocks.

Ovarian Cancer Stocks Recent News

Date Stock Title
May 31 MYGN QIAGEN (QGEN) Develops Test for Research and CDx Application
May 30 NKTR Nektar Management to Present at Upcoming Investor Conferences
May 30 MYGN QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30 NXTC NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
May 30 NKTR Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
May 30 MRUS Merus announces pricing of upsized public offering of common shares
May 30 MRUS Merus Announces Pricing of Upsized Public Offering of Common Shares
May 29 MRUS These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat
May 29 POAI Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
May 29 MRUS Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 29 POAI Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
May 28 NKTR Nektar files to sell 25M shares of common stock for holders
May 28 MRUS Merus announces proposed public offering of common shares
May 28 MRUS Merus N.V. Announces Proposed Public Offering of Common Shares
May 28 POAI Predictive Oncology gains, to present positive results from a retrospective study
May 28 POAI Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 28 MRUS Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
May 27 MRUS Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
Ovarian Cancer

Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. These symptoms may include bloating, pelvic pain, abdominal swelling, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver.The risk of ovarian cancer increases in women who have ovulated more over their lifetime. This includes those who have never had children, those who begin ovulation at a younger age and those who reach menopause at an older age. Other risk factors include hormone therapy after menopause, fertility medication, and obesity. Factors that decrease risk include hormonal birth control, tubal ligation, and breast feeding. About 10% of cases are related to inherited genetic risk; women with mutations in the genes BRCA1 or BRCA2 have about a 50% chance of developing the disease. The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma. There are five main subtypes of ovarian carcinoma, of which high-grade serous carcinoma is the most common. These tumors are believed to start in the cells covering the ovaries, though some may form at the Fallopian tubes. Less common types of ovarian cancer include germ cell tumors and sex cord stromal tumors. A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery.Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks. Those at very high risk may have their ovaries removed as a preventive measure. If caught and treated in an early stage, ovarian cancer is often curable. Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Outcomes depend on the extent of the disease, the subtype of cancer present, and other medical conditions. The overall five-year survival rate in the United States is 45%. Outcomes are worse in the developing world.In 2012, new cases occurred in 239,000 women. In 2015 it was present in 1.2 million women and resulted in 161,100 deaths worldwide. Among women it is the seventh-most common cancer and the eighth-most common cause of death from cancer. The typical age of diagnosis is 63. Death from ovarian cancer is more common in North America and Europe than in Africa and Asia.

Browse All Tags